AIMS: To evaluate the expression of androgen receptors (AR) and two androgen-induced proteins [apolipoprotein D (ApoD) and pepsinogen C (PepC)] in ductal carcinoma in situ (DCIS) of the breast. METHODS AND RESULTS: AR, ApoD and PepC expression was examined in 28 cases of pure DCIS and in 31 cases of DCIS adjacent to invasive carcinoma of the breast using immunohistochemical methods and then correlated with the architectural subtype, the degree of differentiation and the ostrogen receptor (ER)/progesterone receptor (PgR)/HER-2 status. We found no significant differences between pure DCIS and DCIS adjacent to invasive breast cancer regarding the percentage of positive cases for ApoD (64.3% versus 54.8%), PepC (42.9% versus 48.4%), ER (64.3% versus 58.1%), PgR (60.7% versus 58.1%) and HER-2 (39.3% versus 67.7%). However, there was a significantly higher percentage of AR+ DCIS among those adjacent to invasive carcinomas of the breast than among pure DCIS lesions (93.5% versus 60.9%) (P = 0.009). AR expression did not correlate with architectural subtype, degree of differentiation, or ER/PgR/HER-2/ApoD/PepC status, in cases of pure DCIS, nor in DCIS adjacent to invasive carcinoma of the breast. CONCLUSIONS: AR expression may represent an independent predictive factor in DCIS of the breast.
AIMS: To evaluate the expression of androgen receptors (AR) and two androgen-induced proteins [apolipoprotein D (ApoD) and pepsinogen C (PepC)] in ductal carcinoma in situ (DCIS) of the breast. METHODS AND RESULTS: AR, ApoD and PepC expression was examined in 28 cases of pure DCIS and in 31 cases of DCIS adjacent to invasive carcinoma of the breast using immunohistochemical methods and then correlated with the architectural subtype, the degree of differentiation and the ostrogen receptor (ER)/progesterone receptor (PgR)/HER-2 status. We found no significant differences between pure DCIS and DCIS adjacent to invasive breast cancer regarding the percentage of positive cases for ApoD (64.3% versus 54.8%), PepC (42.9% versus 48.4%), ER (64.3% versus 58.1%), PgR (60.7% versus 58.1%) and HER-2 (39.3% versus 67.7%). However, there was a significantly higher percentage of AR+ DCIS among those adjacent to invasive carcinomas of the breast than among pure DCIS lesions (93.5% versus 60.9%) (P = 0.009). AR expression did not correlate with architectural subtype, degree of differentiation, or ER/PgR/HER-2/ApoD/PepC status, in cases of pure DCIS, nor in DCIS adjacent to invasive carcinoma of the breast. CONCLUSIONS: AR expression may represent an independent predictive factor in DCIS of the breast.
Authors: German Perdomo; Dae Hyun Kim; Ting Zhang; Shen Qu; Elizabeth A Thomas; Frederico G S Toledo; Sandra Slusher; Yong Fan; David E Kelley; H Henry Dong Journal: J Lipid Res Date: 2010-02-02 Impact factor: 5.922
Authors: Luis O Gonzalez; Maria D Corte; Julio Vazquez; Sara Junquera; Rosario Sanchez; Ana C Alvarez; Juan C Rodriguez; Maria L Lamelas; Francisco J Vizoso Journal: BMC Cancer Date: 2008-05-28 Impact factor: 4.430
Authors: Suthat Chottanapund; M B M Van Duursen; Kumpol Ratchaworapong; Panida Navasumrit; Mathuros Ruchirawat; Martin Van den Berg Journal: Med Sci (Basel) Date: 2016-09-14
Authors: Choong Man Lee; Il Yong Chung; Yangsoon Park; Keong Won Yun; Hwi Gyeong Jo; Hye Jin Park; Hee Jin Lee; Sae Byul Lee; Hee Jeong Kim; Beom Seok Ko; Jong Won Lee; Byung Ho Son; Sei Hyun Ahn; Jisun Kim Journal: J Breast Cancer Date: 2020-12-24 Impact factor: 3.588
Authors: James C McConnell; Oliver V O'Connell; Keith Brennan; Lisa Weiping; Miles Howe; Leena Joseph; David Knight; Ronan O'Cualain; Yit Lim; Angela Leek; Rachael Waddington; Jane Rogan; Susan M Astley; Ashu Gandhi; Cliona C Kirwan; Michael J Sherratt; Charles H Streuli Journal: Breast Cancer Res Date: 2016-01-08 Impact factor: 6.466